Apyx Medical Corporation (APYX)
Nasdaq · Healthcare · Medical Devices
$2.60+1.96%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $110M
- 52-week range
- $2.32 – $5.08
- 52-week change
- −11.76%
- EPS (trailing)
- −$0.20
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $52.8M (+9.86%)
- Net income
- −$11.2M
- Operating margin
- −12.2%
- Free cash flow
- −$9.1M
From the company’s annual report on SEC EDGAR.
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Headquarters: Clearwater, United States · 205 employees · apyxmedical.com